CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis
December 16, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Reports Third Quarter 2019 Financial Results and Business Update
November 06, 2019 16:04 ET
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity
November 05, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019
October 24, 2019 09:00 ET
|
CohBar, Inc.
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing...
CohBar Expands Board with Biotech Veteran Misha Petkevich
October 23, 2019 08:45 ET
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and...
CohBar to Present at the 2019 BIO Investor Forum
October 15, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and...
CohBar to Present at the 2019 Cantor Global Healthcare Conference
September 18, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases...
CohBar Reports Second Quarter 2019 Financial Results and Business Update
August 07, 2019 16:05 ET
|
CohBar, Inc.
Company to host conference call and webcast today, August 7th, at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology...
CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019
July 31, 2019 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions
June 10, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat age-related...